NIH R01 · 2025
Women are significantly more likely to develop Alzheimer’s disease than men, making up 2/3 of all AD cases. Growing evidence suggests that this difference is related to the decline in ovarian hormone levels experienced by women at midlife through menopause. Women who experience menopause later in life, and thus have a longer lifespan exposure to ovarian hormones, are less likely to develop AD, suggesting that ovarian hormones provide some protection against the development of AD pathology. Reduced brain metabolism and disruption of intrinsic network connectivity are two early indicators of the development of AD pathology observable at midlife. As ovarian hormones, particularly estrogen, are…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.